Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

FDA clears single-use, fully disposable endovascular robotic system
The new Liberty System allows users to remotely deliver and manipulate guidewires and catheters during peripheral endovascular procedures.
New York cardiologist headed to prison—DOJ says he paid for referrals, performed unneeded procedures
"Today’s sentence sends a deterrent message to doctors and the healthcare industry," according to a DOJ statement. "If you abuse patient trust for profit, you will face justice."
Abbott’s dissolving stent picks up a key approval
It's another big victory for Abbott's bioresorbable stent for BTK PAD.
FDA announces new recall of self-expanding stents due to risk of ‘serious harm’
The Class I recall includes more than 26,000 vascular stents from Boston Scientific. These devices have been linked to a risk of potential resistance when the stent delivery system is being withdrawn.
Cardiovascular device approvals continue to lead the FDA's Breakthrough Device Program
Cardiology is number one in FDA Breakthrough Device designations at 218, the highest number out of all other clinical categories. This includes 16 new devices cleared in the past year.

FDA clears single-use, fully disposable endovascular robotic system

The new Liberty System allows users to remotely deliver and manipulate guidewires and catheters during peripheral endovascular procedures.

court judge gavel business man bankruptcy lawsuit

New York cardiologist headed to prison—DOJ says he paid for referrals, performed unneeded procedures

"Today’s sentence sends a deterrent message to doctors and the healthcare industry," according to a DOJ statement. "If you abuse patient trust for profit, you will face justice."

The Abbott Esprit BTK everolimus-eluting biosorbable scaffold system for below the knee peripheral artery disease on display at TCT 2024. Photo by Dave FornellTCTn 2024 DF

Abbott’s dissolving stent picks up a key approval

It's another big victory for Abbott's bioresorbable stent for BTK PAD.

FDA announces new recall of self-expanding stents due to risk of ‘serious harm’

The Class I recall includes more than 26,000 vascular stents from Boston Scientific. These devices have been linked to a risk of potential resistance when the stent delivery system is being withdrawn.

The U.S. Food and Drug Administration (FDA) updated the Breakthrough Device Program designations data this week, which now includes 1,176 Breakthrough Device designations, of which 160 have gained market clearance. Cardiovascular devices lead these with 243 devices, the highest number out of all other clinical categories. This includes 16 new cardiovascular devices cleared in the past year.

Cardiovascular device approvals continue to lead the FDA's Breakthrough Device Program

Cardiology is number one in FDA Breakthrough Device designations at 218, the highest number out of all other clinical categories. This includes 16 new devices cleared in the past year.

FDA clears new trial of first-in-class treatment for pulmonary arterial hypertension

The new drug, VTB-10, previously received the FDA's orphan drug designation in 2024.

Instylla Embrace Hydrogel Embolic System

New liquid embolic agent for hypervascular tumors gains FDA’s premarket approval

Instylla's Embrace Hydrogel Embolic System minimizes bleeding risks during the embolization of hypervascular tumors in the peripheral arteries.

healthcare value value-based care money dollar

Salary update: Cardiologist compensation stays steady—thoracic surgeon pay takes a hit

Cardiologist compensation in the United States is experiencing slow, but steady growth. How does it compare to other specialties?